On March 16, 2021 Israeli artificial intelligence firm Nucleai reported that it is partnering with Sheba Medical Center’s ARC Innovation Center for a new strategic data collaboration (Press release, Debiopharm, MAR 16, 2021, https://www.jpost.com/health-science/israeli-ai-firm-nucleai-sheba-launch-partnership-for-data-collaboration-661267 [SID1234576769]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This new partnership will see Nucleai – which works in powered image analysis – gain access to millions of patient records at Israel’s largest hospital, which will include pathology images, clinical data, genomics and radiomics, along with other data modalities.
This is not the first time Nucleai and Sheba have collaborated. The two have an existing collaboration to work on identifying the histological biomarkers that can predict the body’s response to immunotherapy for non-small-cell lung cancer patients.
This was done with the help of Sheba’s Institute of Pathology, a world leader in the field that acts as a center for diagnosis and research for pathology precision medicine.
Together, Nucleai and the ARC Innovation Center formed a team led by the Pathology Institute head Prof. Iris Barshack along with many of Sheba’s and Nucleai’s specialists to identify biomarkers in other cancer types and treatment modalities.
One success to come out of this partnership was a successful study that demonstrated the prediction efficiency of tumor microenvironment AI-based analysis for breast cancer. These findings were presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 conference.
Together, Sheba and Nucleai are working to advance the study of technological and AI-based solutions to aid in the discovery of histological biomarkers.